Related Experiment Videos
Current needs in chemotherapy for bacterial and fungal infections
Abstract:
Failure of therapy for microbial infections may be related to a number of factors, a major one being drug resistance. Although much progress has been made during the past decade, agents are still needed for improved treatment of infections in which clinical success rates remain unsatisfactory. Problem pathogens include enteric bacteria such as Serratia species, Enterobacter species, and a number of nonfermenting gram-negative bacilli, including Pseudomonas species. Gram-positive organisms that continue to pose a significant therapeutic problem are the coagulase-positive and coagulase-negative staphylococci and enterococci. Atypical mycobacterial species offer major therapeutic challenges. No important broad-spectrum antifungal agents of low toxicity have been developed during the past two decades. Any new antibacterial or antifungal agent should be potent, safe, and well tolerated and should possess pharmacokinetic advantages that will lead to more simplified dosing; low cost would be an additional important advantage.
Insights
New antimicrobial and antifungal agents are needed to combat drug-resistant pathogens like Pseudomonas and Staphylococci. Ideal agents should be potent, safe, well-tolerated, cost-effective, and offer dosing convenience.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Therapeutic failures in microbial infections are often linked to antimicrobial resistance.
- Despite advancements, many infections caused by problematic pathogens like Serratia, Enterobacter, Pseudomonas, Staphylococci, Enterococci, and atypical mycobacteria have unsatisfactory clinical success rates.
- The development of broad-spectrum antifungal agents with low toxicity has stagnated over the past two decades.
Purpose of the Study:
- To highlight the urgent need for novel antibacterial and antifungal agents.
- To identify key characteristics of ideal new antimicrobial and antifungal drugs.
Main Methods:
- Literature review and analysis of current challenges in antimicrobial therapy.
- Identification of problematic microbial pathogens and existing therapeutic limitations.
Main Results:
- Drug resistance remains a major factor in treatment failure for various bacterial and mycobacterial infections.
- Significant challenges persist in treating infections caused by gram-negative bacilli, gram-positive cocci, and atypical mycobacteria.
- A critical gap exists in the availability of effective and safe broad-spectrum antifungal agents.
Conclusions:
- New antibacterial and antifungal agents are crucial to address the growing threat of drug resistance.
- Ideal agents must be potent, safe, well-tolerated, possess favorable pharmacokinetics for simplified dosing, and be cost-effective.